Reabold Resources on their Successful Appraisal Well and Nuformix on their Cannabinoid Collaboration Update
If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Reabold Resources on their Successful Appraisal Well and Nuformix on their Cannabinoid Collaboration Update
Sachin Oza, Co-CEO of Reabold Resources (RBD) provides an update on the drilling of the Iecea Mica-1 ("IM-1") appraisal well, located onshore Romania.
Reabold Resources plc is an investing company investing in the exploration and production ("E&P") sector. The Company's investing policy is to acquire direct and indirect interests in exploration and producing projects and assets in the natural resources sector, and consideration is currently given to investment opportunities anywhere in the world.
Dr Dan Gooding, CEO of Nuformix (NFX) provides an update on their strategic cannabinoid collaboration with Ebers Tech Incorporated.
Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.
(Interview starts at 8 minutes 32 seconds)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.